Gara Jalqabaatti › Myeloma Baay’ee › North Carolina › Durham
Qorannoo klinikaalii Myeloma Baay’ee Durham, NC keessatti
Qorannoo 37 Myeloma Baay’ee f Durham fi naannoo isaa (kilomeetira 30 keessatti) hirmaatuu jiru. Qorannoo banaa eenyu akka hirmaatu fi akkamitti garee qorannoo akka quunnaman ilaali.
Takkalaa qorannoo (Ingiliffa)
Qorannoo hirmaatuu barbaadduu? Fuula kana jalatti agarsiisi — $99 guyyaa 30f →
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
Namoota walitti qabaa jiraSadarkaa 3
- Research Site, Chapel Hill · Miili 10 fagaatti
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
Namoota walitti qabaa jiraSadarkaa 3
- Durham VAMC, Durham
- University of North Carolina, Chapel Hill · Miili 10 fagaatti
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
Namoota walitti qabaa jiraSadarkaa 3
- Duke University Medical Center, Durham
A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events
Namoota walitti qabaa jiraSadarkaa 2
- Duke University Medical Center, Durham
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
Namoota walitti qabaa jiraSadarkaa 3
- Durham VAMC, Durham
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Namoota walitti qabaa jiraSadarkaa 2
- Lineberger Comprehensive Cancer Center, Chapel Hill · Miili 10 fagaatti
A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
Namoota walitti qabaa jiraSadarkaa 2/3
- University of North Carolina at Chapel Hill /ID# 277708, Chapel Hill · Miili 10 fagaatti
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
Namoota walitti qabaa jiraSadarkaa 3
- Duke University, Durham
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
Namoota walitti qabaa jiraSadarkaa 2
- University of North Carolina Medical Center, Chapel Hill · Miili 10 fagaatti
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
Namoota walitti qabaa jiraSadarkaa 1/2
- University of North Carolina at Chapel Hill /ID# 272454, Chapel Hill · Miili 10 fagaatti
HCMT/MM2401: Ph2 Study of Selinexor + Bispecific Antibody for RRMM
Namoota walitti qabaa jiraSadarkaa 2
- Duke University Health System, Durham
Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
Namoota walitti qabaa jiraSadarkaa 1
- University of North Carolina Hospitals at Hillsborough, Hillsborough · Miili 13 fagaatti
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
Namoota walitti qabaa jiraSadarkaa 1/2
- GSK Investigational Site, Chapel Hill · Miili 10 fagaatti
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
Namoota walitti qabaa jiraSadarkaa 1
- Duke University Hospital, Durham
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
Namoota walitti qabaa jiraSadarkaa 1/2
- Research Site, Durham
DISCOVERY: Evaluating a Decision Support Tool for Adults Seen in Hematology/Oncology Clinics
Namoota walitti qabaa jira
- Lineberger Comphrehensive Cancer Center at University of North Carolina, Chapel Hill · Miili 10 fagaatti
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
Namoota walitti qabaa jiraSadarkaa 3
- Research Site, Durham
- Research Site, Chapel Hill · Miili 10 fagaatti
A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
Namoota walitti qabaa jiraSadarkaa 1
- Duke Cancer Center, Durham
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
Namoota walitti qabaa jiraSadarkaa 2
- UNC Hospitals Adult Oncology Clinics, Chapel Hill · Miili 10 fagaatti
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
Namoota walitti qabaa jiraSadarkaa 1/2
- University of North Carolina at Chapel Hill /ID# 274667, Chapel Hill · Miili 10 fagaatti
Selinexor and Backbone Treatments of Multiple Myeloma Patients
Namoota walitti qabaa jiraSadarkaa 1/2
- Duke Institute of Cancer/ Duke University, Durham
A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
Namoota walitti qabaa jiraSadarkaa 1
- University of North Carolina /ID# 251203, Chapel Hill · Miili 10 fagaatti
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
Namoota walitti qabaa jiraSadarkaa 1
- University of North Carolina at Chapel Hill, Chapel Hill · Miili 10 fagaatti
A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)
Namoota walitti qabaa jiraSadarkaa 2
- University of North Carolina (Data Collection Only), Chapel Hill · Miili 10 fagaatti
Registry of Older Patients With Cancer
Namoota walitti qabaa jiraQorannoo ilaalaa
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill · Miili 10 fagaatti
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
Namoota walitti qabaa jiraSadarkaa 3
- Duke University, Durham
Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma
Namoota walitti qabaa jiraSadarkaa 2
- University of North Carolina, Chapel Hill · Miili 10 fagaatti
Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
Namoota walitti qabaa jiraSadarkaa 2
- Duke Comprehensive Cancer Center, Durham
- University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center, Chapel Hill · Miili 10 fagaatti
Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma
Namoota walitti qabaa jiraSadarkaa 1
- University of North Carolina Hospitals at Hillsborough, Chapel Hill · Miili 10 fagaatti
A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment
Namoota walitti qabaa jiraSadarkaa 1/2
- Duke University Health System (DUHS), Durham
Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma
Namoota walitti qabaa jiraSadarkaa 1
- University Of North Carolina Health Care - Hillsborough Campus /ID# 278230, Hillsborough · Miili 13 fagaatti
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
Namoota walitti qabaa jiraSadarkaa 1
- University of North Carolina, Chapel Hill · Miili 10 fagaatti
Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)
Namoota walitti qabaa jiraSadarkaa 1
- University of North Carolina, Chapel Hill · Miili 10 fagaatti
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Namoota walitti qabaa jiraSadarkaa 1/2
- Duke University, Durham
- UNC Hospital, Chapel Hill · Miili 10 fagaatti
Registry for Adults With Plasma Cell Disorders (PCD's)
Namoota walitti qabaa jiraQorannoo ilaalaa
- North Carolina Cancer Hospital, Chapel Hill · Miili 10 fagaatti
Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
Namoota walitti qabaa jiraQorannoo ilaalaa
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill · Miili 10 fagaatti
CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
Namoota walitti qabaa jiraSadarkaa 1
- Duke University Health System (DUHS), Durham
Qorannoo Myeloma Baay’ee magaalota biroo keessatti
- New York City, NYQorannoo 60
- Boston, MAQorannoo 42
- Atlanta, GAQorannoo 42
- Houston, TXQorannoo 38
- Nashville, TNQorannoo 32
- Denver, COQorannoo 27
- Rochester, MNQorannoo 24
- St. Louis, MOQorannoo 24
- Columbus, OHQorannoo 24
- Baldwin Park, CAQorannoo 23
- Edison, NJQorannoo 22
- Chicago, ILQorannoo 22
Qorannoo biroo Durham keessatti
- Saree OljooQorannoo 64
- Saree (Gosoota Hunda)Qorannoo 58
- Kansara Qara'a Non-Small CellQorannoo 39
- Leukemia Myeloidii HamaaQorannoo 33
- Kansara MetastatikiiQorannoo 33
- Kansarii ProstateQorannoo 32
- Dhibee QaraQorannoo 32
- Kansarii ColorectalQorannoo 28
- Kansarii OvariiQorannoo 27
- Luukemiya Limfoositiikii KeessummaaQorannoo 27
- Cufama OnneeQorannoo 26
- Kansarii PancreasQorannoo 24
Kanneen ClinicalTrials.gov irraa argaman, daataa 06-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.